Tversky-Kahneman 1971 and Gilovich-Vallone-Tversky 1985 established that humans systematically misread short random sequences. Indian NSE/SEBI behavioural data show retail investors compound the error. A counter-measure checklist plus an illustrative Titan Biotech FY25 case study of process-over-pattern corporate behaviour.

Peter Lynch's Price-to-Earnings-to-Growth ratio reframes valuation: a high P/E may be cheap if growth is high, a low P/E may be a trap if growth is fading. Using Titan Biotech FY25 audited inputs (10-yr revenue CAGR ~15%, 10-yr PAT CAGR ~29%, CFO/Operating Profit ~103%) as a clean educational illustration.

Daniel Kahneman and Dan Lovallo's 1993 distinction between the Inside View (story-driven) and the Outside View (reference-class base rates) is the most powerful behavioural upgrade an Indian long-term investor can make. We illustrate it with Titan Biotech's FY25 audited numbers, presented strictly as an educational case study of management process — not a valuation call.